DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Clinical trial NCT04229355 · UNKNOWN
Trial details
- NCT number
- NCT04229355
- Sponsor
- Guangxi Medical University
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-02
- Primary completion
- 2022-12-30
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.